Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology

Complications & Structural Monitoring

At a Glance

Intermediate uveitis can threaten vision through macular swelling, cataracts, high eye pressure, scar tissue, or retinal problems, sometimes without pain. Regular retinal scans, eye-pressure checks, and eye examinations help detect changes early and guide treatment.

While intermediate uveitis is often painless, it can lead to structural changes in the eye that threaten your vision. These complications are often the result of chronic inflammation or, in some cases, the very treatments used to control it [1][2]. This is why your medical team requires regular monitoring with specialized scans and pressure checks, even when you feel your symptoms are well-managed.

The Primary Threat: Cystoid Macular Edema (CME)

A major cause of vision loss in intermediate uveitis is Cystoid Macular Edema (CME) [1]. This occurs when inflammation causes the tiny blood vessels in the retina to leak fluid. This fluid collects in the macula—the part of the eye responsible for sharp, central vision—forming small fluid pockets or “cysts” [3][4].

  • How it’s monitored: Doctors use Optical Coherence Tomography (OCT) to see these microscopic fluid pockets. While using an Amsler grid at home (a grid of straight lines) can help you notice central distortion, CME can be present even when your vision feels “okay,” so OCT scans and clinical exams remain the gold standard for tracking swelling [5][4].
  • How it’s treated: The goal is to dry out the macula by stopping the underlying inflammation, often using oral medications, immunomodulators, or intravitreal implants [5][6].

Treatment-Related Complications

Corticosteroids are powerful tools for stopping inflammation, but they come with a high “cost” for the eye’s structure over time. Do not stop a prescribed drop or pill on your own; always coordinate changes with your doctor.

Cataracts

A cataract is a clouding of the eye’s natural lens. In intermediate uveitis, cataracts can be caused by the inflammation itself or by prolonged steroid use [7].

  • The Risk: The risk of cataracts increases with the dose, duration, and route of steroid treatment (e.g., frequent eye drops, repeated periocular injections, or intravitreal implants carry a high risk) [7][8].
  • Surgery: If a cataract blurs your vision significantly, it can be removed surgically. However, the eye must typically be “quiet” (free of active inflammation) for several months before surgery to ensure a good result and prevent a major flare-up afterward [9][10].

Glaucoma and Ocular Hypertension

Steroids and intraocular inflammation can both interfere with the eye’s ability to drain fluid, leading to high intraocular pressure (IOP) [2]. If this pressure remains high, it can damage the optic nerve, leading to glaucoma and permanent vision loss [11][12].

  • Monitoring: Your clinician will set a monitoring interval based on your specific treatment and risk factors to check your eye pressure regularly.
  • Management: Elevated pressure is often treatable. Many steroid responders can manage the pressure with daily eye drops, though some may require multiple agents, laser therapies, or surgery to help the eye drain fluid properly [12][13].

Other Structural Changes

As inflammation persists, it can “pull” on the delicate tissues inside the eye:

  • Epiretinal Membrane (ERM): This is a thin, scar-like tissue that grows over the surface of the macula, sometimes called a “macular pucker” [14]. It can make your vision wavy or distorted, which is another reason sudden distortion requires urgent evaluation. If it becomes severe, it may need to be surgically removed [15].
  • Retinal Detachment: Chronic inflammation can cause the vitreous gel to shrink and pull on the retina, potentially causing it to tear or detach [16][17]. A suspected detachment requires immediate specialist assessment; treatment varies and may involve observation, laser, or surgery depending on the findings.
  • Vitreous Hemorrhage: Inflammation or new, abnormal blood vessels can bleed into the vitreous gel, causing a sudden burst of floaters or a dark “cloud” in your vision [18].
  • Optic-Disc Edema: This is swelling of the optic nerve head, which can occur during active flares and contribute to vision loss if not addressed [19][20].

Common questions in this guide

Why can intermediate uveitis affect vision even when there is no eye pain?
Intermediate uveitis is often painless, but ongoing inflammation can leak fluid into the macula, the part of the retina used for sharp central vision. It can also lead to cataracts, high eye pressure, scar tissue, or retinal problems, so regular eye examinations are important.
What is cystoid macular edema, and how is it detected?
Cystoid macular edema is a buildup of small fluid pockets in the macula caused by inflammation. An OCT scan can show this swelling even when your vision seems normal; treatment focuses on controlling inflammation and may include oral medicine, immune-modifying medicine, or an implant placed inside the eye.
Can steroid treatment cause cataracts or glaucoma in intermediate uveitis?
Yes. Inflammation and corticosteroids can cloud the lens and raise pressure inside the eye, and pressure that stays high can damage the optic nerve. Risk depends on the steroid dose, duration, and route, so do not stop a prescribed steroid without medical guidance.
How often should eye pressure be checked during steroid treatment?
The monitoring interval depends on your steroid treatment, response, and individual risk factors. People using local steroid injections or implants may need planned pressure checks, and high pressure is often treated with eye drops but may sometimes require laser treatment or surgery.
When is cataract surgery considered for someone with intermediate uveitis?
Cataract surgery may be considered when lens clouding significantly blurs vision. The eye usually needs to be quiet, without active inflammation, for several months before surgery, and the ophthalmology team will plan ways to reduce the chance of a flare afterward.
Which vision changes need urgent assessment?
New waviness or distortion, a sudden burst of floaters, or a dark cloud in your vision should prompt urgent evaluation. A suspected retinal detachment needs immediate specialist assessment, and sudden changes should not be watched at home without contacting your eye-care team.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Intermediate uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current 'central macular thickness' on the OCT scan, and has it changed since my last visit?
  2. 2.How often do we need to check my eye pressure (IOP) to ensure I am not having a 'steroid response'?
  3. 3.Is my eye currently quiet enough to consider cataract surgery, and what is the plan to prevent a flare-up after the procedure?
  4. 4.Do you see any signs of an epiretinal membrane or 'macular pucker' that could be distorting my vision?
  5. 5.If we use a local steroid injection, what is the specific monitoring schedule to catch potential glaucoma early?

References

References (20)
  1. 1

    Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis.

    Ozdal PC, Berker N, Tugal-Tutkun I

    Journal of ophthalmic & vision research 2015; (10(4)):469-80 doi:10.4103/2008-322X.176897.

    PMID: 27051493
  2. 2

    Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.

    Ophthalmology 2015; (122(10)):1976-86.

    PMID: 26298718
  3. 3

    Correlation between Morphological Characteristics of Macular Edema and Visual Acuity in Young Patients with Idiopathic Intermediate Uveitis.

    Iannetti L, Scarinci F, Alisi L, et al.

    Medicina (Kaunas, Lithuania) 2023; (59(3)) doi:10.3390/medicina59030529.

    PMID: 36984530
  4. 4

    Patterns of Macular Edema in Uveitis as Diagnosed by Optical Coherence Tomography in Tertiary Eye Center.

    Gupta S, Shah DN, Joshi SN, et al.

    Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2018; (10(19)):39-46 doi:10.3126/nepjoph.v10i1.21687.

    PMID: 31056575
  5. 5

    Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant.

    Rossetto JD, Nascimento H, Fernandes DD, et al.

    Arquivos brasileiros de oftalmologia 2015; (78(3)):190-3.

    PMID: 26222112
  6. 6

    Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.

    Cai CX, Skalak C, Keenan RT, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2020; (258(5)):1023-1030 doi:10.1007/s00417-020-04614-x.

    PMID: 32114654
  7. 7

    Risk of Cataract in Intermediate Uveitis.

    Minkus CL, Pistilli M, Dreger KA, et al.

    American journal of ophthalmology 2021; (229()):200-209 doi:10.1016/j.ajo.2021.02.032.

    PMID: 33713679
  8. 8

    Risk Factors for the Development of Cataract in Children with Uveitis.

    Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al.

    American journal of ophthalmology 2017; (177()):139-143 doi:10.1016/j.ajo.2017.02.023.

    PMID: 28257832
  9. 9

    Prognostic factors of cataract surgery in patients with uveitis.

    Jevnikar K, Počkar S, Umek L, et al.

    International ophthalmology 2023; (43(12)):4605-4612 doi:10.1007/s10792-023-02860-6.

    PMID: 37697081
  10. 10

    Phacoemulsification with Intraocular Lens Implantation in Pediatric Uveitis: A Retrospective Study.

    Ganesh SK, Mistry S

    Ocular immunology and inflammation 2018; (26(2)):305-312 doi:10.1080/09273948.2016.1206944.

    PMID: 27598822
  11. 11

    Long-Term Outcomes of Pediatric Idiopathic Intermediate Uveitis.

    AlBloushi AF, Solebo AL, Gokhale E, et al.

    American journal of ophthalmology 2022; (237()):41-48 doi:10.1016/j.ajo.2021.11.003.

    PMID: 34780797
  12. 12

    Current management of uveitis-associated ocular hypertension and glaucoma.

    Kesav N, Palestine AG, Kahook MY, Pantcheva MB

    Survey of ophthalmology 2020; (65(4)):397-407 doi:10.1016/j.survophthal.2019.12.003.

    PMID: 31816329
  13. 13

    Ocular Complications of Intermediate Uveitis.

    Amer R, Sharon Y

    Ocular immunology and inflammation 2025; (33(4)):548-555 doi:10.1080/09273948.2024.2378370.

    PMID: 39024511
  14. 14

    Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis.

    Grajewski RS, Boelke AC, Adler W, et al.

    Eye (London, England) 2016; (30(11)):1415-1423 doi:10.1038/eye.2016.133.

    PMID: 27391933
  15. 15

    Surgical management of post-uveitic epiretinal membranes.

    Coassin M, Mori T, Mastrofilippo V, et al.

    European journal of ophthalmology 2021; 11206721211017750 doi:10.1177/11206721211017750.

    PMID: 34011201
  16. 16

    PERIPHERAL RETINOSCHISIS IN INTERMEDIATE UVEITIS.

    Pichi F, Srivastava SK, Nucci P, et al.

    Retina (Philadelphia, Pa.) 2017; (37(11)):2167-2174 doi:10.1097/IAE.0000000000001463.

    PMID: 28590967
  17. 17

    Analysis of clinical features and visual outcomes of pars planitis.

    Berker N, Sen E, Elgin U, et al.

    International ophthalmology 2018; (38(2)):727-736 doi:10.1007/s10792-017-0526-2.

    PMID: 28389773
  18. 18

    Vitreous hemorrhage in patients with uveitis: a comparative study between adults and children.

    Abroug N, Dridi T, Mourali M, et al.

    International ophthalmology 2025; (45(1)):60 doi:10.1007/s10792-024-03403-3.

    PMID: 39918620
  19. 19

    Uveitis in children: Epidemiological, clinical and prognostic characteristics.

    Rodier-Bonifas C, Rochet E, Seve P, et al.

    Journal francais d'ophtalmologie 2023; (46(2)):163-172 doi:10.1016/j.jfo.2022.08.005.

    PMID: 36642594
  20. 20

    Complications in Intermediate Uveitis: Prevalence, Time of Onset, and Effects on Vision in Short-Term and Long-Term Follow-Up.

    Sancho L, Kramer M, Koriat A, et al.

    Ocular immunology and inflammation 2019; (27(3)):447-455 doi:10.1080/09273948.2017.1420203.

    PMID: 29370567

This page is for informational purposes only and does not constitute medical advice. An ophthalmologist should interpret your scans and pressure readings and advise you about urgent vision changes or treatment decisions.